AngioDynamics (ANGO) Expected to Release Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is expected to post its Q1 2027 results before the market opens on Thursday, October 1st. Analysts expect AngioDynamics to announce earnings of ($0.1125) per share and revenue of $80.51 million for the quarter. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Investors may visit the the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Thursday, October 8, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. On average, analysts expect AngioDynamics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

AngioDynamics Stock Up 0.3%

Shares of NASDAQ:ANGO opened at $15.54 on Tuesday. The company’s fifty day simple moving average is $15.31 and its 200 day simple moving average is $12.89. AngioDynamics has a 12 month low of $9.39 and a 12 month high of $16.29. The firm has a market cap of $642.27 million, a price-to-earnings ratio of -17.86 and a beta of 0.33.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANGO shares. HC Wainwright raised their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.50.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is owned by insiders.

About AngioDynamics

AngioDynamics, Inc (NASDAQ: ANGO) is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company’s product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.